From financialisation to innovation in UK Big Pharma : : AstraZeneca and GlaxoSmithKline / / Öner Tulum, Antonio Andreoni, William Lazonick.
The tension between innovation and financialisation is central to the business corporation. Innovation entails a 'retain-and-reinvest' allocation regime that can form a foundation for stable and equitable economic growth. Driven by shareholder-value ideology, financialisation entails a sh...
Saved in:
| VerfasserIn: | |
|---|---|
| TeilnehmendeR: | |
| Place / Publishing House: | Cambridge : : Cambridge University Press,, 2022. |
| Year of Publication: | 2022 |
| Edition: | First edition. |
| Language: | English |
| Series: | Cambridge elements. Elements in reinventing capitalism
|
| Physical Description: | 1 online resource (104 pages) :; digital, PDF file(s). |
| Notes: | Title from publisher's bibliographic system (viewed on 30 Nov 2022). |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- 1. Introduction; 2. Innovation and Competition in the Global Pharmaceutical Industry; 3. The Innovation-Financialisation Tension in the Global Pharmaceutical Industry; 4. AstraZeneca; 5. GlaxoSmithKline; 6. Explaining the Financialisation-to-Innovation Transition at AstraZeneca and GlaxoSmithKline; Appendix; References.